

NewLink Genetics Corporation Investor Relations Department 2503 South Loop Drive Ames, IA 50010 United States

Visit IR website ☐ Sign-up for Email alerts ☐

## **Company Profile**

Founded in 1999, NewLink Genetics is an immuno-oncology company focused on discovering and developing novel products for the treatment of cancer. The drug discovery and development teams at NewLink Genetics are relentlessly pursuing a wide range of immuno-oncology portfolio candidates with the potential to change the oncology landscape. NewLink Genetics' portfolio includes two small-molecule product candidates currently in clinical development. These product candidates inhibit the IDO pathway, a key immuno-oncology target, and focus on breaking the immune system's tolerance to cancer.

## Press Releases [View all]

Jun 23, 2017

Positive Phase 1b Data for NewLink
Genetics' IDO Pathway Inhibitor,
Indoximod, in Combination with
Chemotherapy for Patients with Newly
Diagnosed Acute Myeloid Leukemia (AML)
Presented at the European Hematologic
Association (EHA) Congress in Madrid,
Spain

Jun 8, 2017

NewLink Genetics to Regain Rights to GDC-0919

Jun 5, 2017

NewLink Genetics' Indoximod +
PROVENGE® Results in Statistically
Significant Improvement in Radiographic
Progression-Free Survival (rPFS) for
Patients with Metastatic Castration
Resistant Prostate Cancer (mCRPC) in
Phase 2 Trial

Jun 2, 2017

Results from Clinical Trial of Indoximod
Plus Chemotherapy for Patients with
Metastatic Breast Cancer

May 18, 2017

Data from Clinical Study of NewLink
Genetics' IDO Pathway Inhibitor,
Indoximod, to Be Presented at the 22nd
European Hematology Association
Congress

## Financials [View all]

First Quarter Financial Results

Mar 6, 2017 Annual Report (10-K)

Mar 31, 2017
Proxy Statement (DEF 14A)

May 5, 2017 Quarterly Report (10-Q)

Nov 8, 2016
Quarterly Report (10-Q)

Aug 5, 2016
Quarterly Report (10-Q)